[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myelodysplastic-myeloproliferative-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":99,"states":104},"Myelodysplastic\u002FMyeloproliferative Neoplasm",14,12,[8,16,23,30,36,42,48,54,60,66,73,79,85,92],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07228624","Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes",[12],"Phase 2","RECRUITING","2026-08-26T02:15:46.655893Z","2026-05-05T02:43:26.852525Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04771130","A Study of BGB-11417 in Participants With Myeloid Malignancies",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:49.658025Z","2026-05-05T02:43:28.973819Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05549661","Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome\u002FMPN Overlap Neoplasms",[27],"Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.622435Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[27],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04140487","Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent\u002FRefractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[20],"2026-08-26T02:18:31.164304Z","2026-04-29T02:57:57.109829Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06661915","A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)",[12],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.360451Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06523556","Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm\u002FMyelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia",[20],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.949132Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04771572","Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS\u002FMPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",[27],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.598768Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT03630991","Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",[27],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.485890Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT03964506","Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant",[70],"Early Phase 1","2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.480390Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",[],"2026-08-26T02:19:18.331180Z","2026-05-13T02:55:06.072349Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05875805","A Telehealth Advance Care Planning Intervention",[],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.354626Z",{"nct_id":86,"title":87,"phases":88,"status":89,"updated_at":90,"content_modified":91},"NCT07634536","Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:51.982021Z","2026-06-14T18:39:22.254845Z",{"nct_id":93,"title":94,"phases":95,"status":96,"updated_at":97,"content_modified":98},"NCT04493138","Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic\u002FMyeloproliferative Neoplasm With FLT3 or CBL Mutations",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:33:22.894436Z","2026-05-05T02:43:28.119922Z",[100],{"biomarker":101,"count":102,"slug":103},"Receptor-Type Tyrosine-Protein Kinase FLT3",3,"receptor-type-tyrosine-protein-kinase-flt3",[105,109,113,116,119,122,125,128,131],{"state":106,"count":107,"slug":108},"Texas",6,"texas",{"state":110,"count":111,"slug":112},"California",4,"california",{"state":114,"count":111,"slug":115},"New York","new-york",{"state":117,"count":111,"slug":118},"Ohio","ohio",{"state":120,"count":102,"slug":121},"Florida","florida",{"state":123,"count":102,"slug":124},"Illinois","illinois",{"state":126,"count":102,"slug":127},"North Carolina","north-carolina",{"state":129,"count":102,"slug":130},"Utah","utah",{"state":132,"count":102,"slug":133},"Virginia","virginia"]